Mounjaro alternatives for weight loss: what your options actually are

You've been told Mounjaro might not be available, here's what that actually means

Stock pressures, clinical contraindications, or a prescriber's judgement can all put Mounjaro out of reach for a particular person at a particular moment. The frustration is real. But "Mounjaro alternative" doesn't mean an over-the-counter substitute or a herbal equivalent, it means another prescription medicine assessed by a clinician who knows your full picture. There is no weight-loss alternative to Mounjaro that skips that step.

The two realistic alternatives, both licensed in the UK, are semaglutide as a weekly injection (Wegovy) and, more recently, semaglutide as a daily tablet (Wegovy tablets). They work differently from tirzepatide, the active ingredient in Mounjaro, at a molecular level, carry their own evidence base, and have different practical profiles, injection versus tablet, fridge versus room temperature, weekly versus daily. Understanding those differences is the starting point for any honest conversation with a prescriber.

It's also worth being clear about what isn't an alternative. Ozempic is semaglutide, but it's licensed for type 2 diabetes, not weight management. Rybelsus is oral semaglutide too, again, for diabetes, not weight loss. Saxenda (liraglutide) holds a UK weight-management licence, but its clinical use has broadly been superseded by the more effective newer medicines. A broader look at Mounjaro alternatives covers this landscape in more detail.

Wegovy injection: the established weight-loss alternative to Mounjaro

Wegovy has been available in the UK longer than Mounjaro and has a well-established evidence base. In the STEP 1 trial (68 weeks), semaglutide 2.4 mg produced around 15% average body-weight reduction, a meaningful result, and one validated in the original STEP 1 publication in the New England Journal of Medicine. The SURMOUNT-5 head-to-head trial (2025) did find tirzepatide produced greater average loss than semaglutide 2.4 mg, but that comparison is shifting as Wegovy's dosing ceiling rises.

The MHRA approved a 7.2 mg maintenance dose of Wegovy in January 2026, and in April 2026 approved a dedicated single-dose 7.2 mg pen, one pre-set weekly injection with a built-in covered needle. Trials at 7.2 mg reported around 20.7% average weight loss over 72 weeks, which meaningfully narrows the gap with tirzepatide's top dose. That pen is intended for adults with a BMI of 30 or above; specific dose availability is something a prescriber confirms at consultation.

Wegovy is a once-weekly subcutaneous injection. It needs to be kept in the fridge, most people keep it in the fridge door alongside everyday items and inject on the same day each week. The side-effect profile is predominantly gastrointestinal (nausea, digestive discomfort, changes in bowel habit) and tends to be most noticeable after starting or increasing the dose. You can read more about treatment options for weight loss and how injection-based medicines fit into a broader plan.

Wegovy tablets: the newer oral alternative to Mounjaro

For people who'd rather not inject at all, the oral semaglutide tablet became the first option in this class to be UK-licensed for weight management when the MHRA approved it on 11 June 2026, the UK was the first country in Europe to do so. The dosing schedule moves from 1.5 mg up through 4 mg and 9 mg to a 25 mg maintenance dose, with at least a month at each level.

The tablet is taken first thing in the morning on an empty stomach with a small amount of plain water (no more than about 120 ml) and patients need to wait at least 30 minutes before food, coffee, or other oral medicines. Swallowed whole. No refrigeration required, which makes it the most travel-friendly option in this class.

In the OASIS 4 phase-3 trial (307 adults, 64 weeks), participants on the tablet achieved around 13.6% average weight loss compared with around 2.4% on placebo, alongside lifestyle changes. Among participants who stayed fully adherent to treatment, average loss was around 16.6%. The most common side effects were gastrointestinal, reported by around 74% of participants on the active medicine versus 42% on placebo, and were generally mild to moderate. How Mounjaro compares with weight-loss tablets goes deeper into that specific trade-off. If a tablet-based approach interests you, a tablet alternative to Mounjaro is one of the questions our prescribers address most often.

As of summer 2026, Wegovy tablets are available on private prescription only, a NICE appraisal would be needed before NHS funding. The NICE appraisal of tirzepatide (TA1026) gives useful background on how NICE assesses this class of medicine. On the question of cost, our treatment page sets out what a private prescription includes; whether any of these alternatives are available over the counter is a question worth reading before assuming you have more options than you do.

Which alternative is right for you, and how a prescriber works that out

There is no universal answer. A prescriber weighs your BMI, any weight-related conditions, your medication list, your previous experience with these medicines if you've used them, and your practical preferences. For most adults meeting the licensed criteria (BMI of 30 or above, or 27 or above with a qualifying condition), both Wegovy injection and Wegovy tablets are clinically viable routes when Mounjaro is unsuitable or unavailable. The oral option makes sense for some; the injection suits others better.

One factor that gets less attention: people already taking an oral contraceptive pill who start tirzepatide are advised to add a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide may reduce absorption of the pill. NHS guidance doesn't flag the same concern for semaglutide. That's exactly the kind of detail a prescriber factors in when recommending one treatment over another, details you might not encounter if you're simply comparing headline weight-loss percentages.

If you're considering your options, the practical next step is a clinical consultation. Our prescribers at nume review your consultation the same day, a named clinician reads it, not automated software. From there you'll get a clear recommendation, or a clear explanation of why a particular medicine isn't the right fit. Whether there's an alternative to Mounjaro for your specific situation is exactly the kind of question that needs that conversation. When you're ready, starting your free consultation is the first step.